Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP
Corbus Pharmaceuticals — Investor Presentation (November 2014)
26 slides from Corbus Pharmaceuticals's investor presentation, Nov 10, 2014
Slide 1: Developing Breakthrough Therapies for Rare Inflammatory Diseases
Exhibit 99.1 OTCQB: CRBP www.CorbusPharma.com Developing Breakthrough Therapies for Rare Inflammatory Diseases
Slide 2: Forward-Looking Statement
2 Forward-Looking Statement This presentation contains certain forward-looking statements, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies
Slide 3: Overview
3 Overview • Corbus Pharma is focusing on rare, life-threatening, chronic inflammatory diseases • Lead drug Resunab™: a first-in-class oral anti-inflammatory/fibrosis small molecule • Acts to trigger inflammatory resolution: the “off” switch for chronic inflammation • Proven safe in Phase 1 + promis
Slide 4: Our Target Indications: Current & Future
4 Our Target Indications: Current & Future Patient numbers Estimated Current therapies for Drawbacks to current Indication (USA) Market size inflammation therapies Current lead indications: Cystic Fibrosis 30,000 >$3B Steroids, ibuprofen Considerable side effects Diffuse Systemic Steroids, Sclerosis
Slide 5: CB2 Receptor: Turns inflammation "off"
55 CB2 Receptor: Turns inflammation “off” • CB2 receptor is present on immune cells and activated by endogenous lipid mediators • Activation of CB2 turns inflammation off (“inflammatory resolution”) • Resunab expected to be first CB2-binding anti-inflammatory drug to reach market • Upstream of other
Slide 6: Published research on lipoxin pathway and fibrosis
LLsizl Stefan EXTENOED REPORT The 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis Gerhard Krénks."# Nicole Reich,’ Carina Scholtysek,'? Alfiys Akhmetshina.’ Udderhardt,'? Pawel Zerr,’ Katrin Oliver Cistler.’ Georg Schett.’ Jérg HW Distler’ Palurrbo,’ Veronika L
Slide 7: Resunab
77 Resunab • Resunab: synthetic oral CB2 agonist small-molecule • Designed to trigger the resolution of chronic inflammation • Full manufacturing, drug supply, non-clinical safety & pharmacology package for Phase 2 programs • Excellent clinical safety profile to date: two prior Phase 1 clinical tria
Slide 8: Resunab: Only CB2-Agonist Targeting Inflammation
8 Resunab: Only CB2-Agonist Targeting Inflammation Company Indication Brain penetration Status Affects CNS Entering Corbus Pharma Inflammation Minimal No Phase 2 AbbVie Pain Full Phase 1 Yes Glenmark Pain Full Phase 1 Yes Eli Lilly Knee pain Full Phase 2 Yes AstraZeneca Post operative pain Full Phas
Slide 9: Cystic Fibrosis
9 Cystic Fibrosis Targeting inflammation at the core of the disease
Slide 10: Overview: Cystic Fibrosis
10 10 Overview: Cystic Fibrosis • Inflammatory orphan disease (30,000 patients in USA, 75,000 WW) • Average life expectancy of CF patients is approximately 40 years • Inflammation at core of disease‘s morbidity and mortality (pulmonary fibrosis) • Very high doses of steroids/ibuprofen effective but
Slide 11: Resunab targets key CF inflammatory players
11 Resunab targets key CF inflammatory players TGF- Lipoxin-A4 • Genetically linked to disease • Absent in CF lungs • Associated with worsening symptoms • Replacement therapy effective in animal models CFTR defect Underlying Infection Fibrosis Inflammation Kalydeco Resunab Antibiotics Resunab (for 6
Slide 12: Resunab Reduces Pulmonary Fibrosis In Animal Models
12 Resunab Reduces Pulmonary Fibrosis In Animal Models Alveoli -air sacs Fibrosis-inducing agent (Bleomycin) administered to lungs day 1 followed by daily oral Resunab for 21 days Control 350 P<.004 300 250 200 Bleomycin 150 100 50 0 Bleomycin+ Resunab Control Bleomycin Bleomycin therapy + Resunab G
Slide 13: Resunab Planned Cystic Fibrosis Phase 2 Trial
13 Resunab Planned Cystic Fibrosis Phase 2 Trial • Double blind placebo control study in the USA under IND from FDA • Primaryend points:Safety/tolerability + PK • Secondary end points:Inflammatory biomarkers+ MOA + change in clinical outcome measures • Patient number: 70 adults with CF in 15-20 site
Slide 14: Diffuse Systemic Sclerosis ("Scleroderma")
14 Diffuse Systemic Sclerosis (“Scleroderma”) Relief for a disease with no effective long-term therapy
Slide 15: Overview: Diffuse Systemic Sclerosis (Scleroderma)
15 Overview: Diffuse Systemic Sclerosis (Scleroderma) • Chronic inflammatory disease causing fibrosis of skin, joints and internal organs • Orphan disease (50,000 patients in USA) • 80% of patients are women in their 30’s and 40’s • Common cause of death: lung fibrosis (50% mortality in 10 years) •
Slide 16: Resunab Inhibits Key Factors in SSC
16 Resunab Inhibits Key Factors in SSC • TGF-beta plays key role in SSC progression (same in CF and IPF) • Elevated TGF-beta levels associated with disease progression • Strong Resunab efficacy data in animal models • Resunab reduces TGF-beta and collagen in skin fibroblasts from SSC patients Health
Slide 17: Resunab Inhibits Skin Thickening In Mouse SSC Model
17 Resunab Inhibits Skin Thickening In Mouse SSC Model Healthy skin Thick skin induced by Near normal skin after oral Bleomycin Resunab taken once daily for four weeks Control Bleomycin Bleomycin + Resunab Gonzales et.al., Annals of Rheumatic Diseases, April 4, 2012
Slide 18: Resunab: Planned SSC Phase 2 Clinical Trial
18 Resunab: Planned SSCPhase 2 Clinical Trial • Double blind placebo control study in USA under IND from FDA • Primary end points:Safety/tolerability + PK+ Change in clinical outcomes • Secondary end points:Inflammatory biomarkers+ quality of life (QOL) • Patient number:35 adults with SSC with 8-10
Slide 19: Management Team
19 Management Team Yuval Cohen, Ph.D.- Chief Executive Officer • Co-founder and former President of Celsus Therapeutics (CLTX) • Expertise in developing anti-inflammatory drugs including for CF Mark Tepper, Ph.D.- President & Chief Scientific Officer • Former VP USA Research & Operations, EMD Serono
Slide 20: Board of Directors
20 Board of Directors Yuval Cohen, Ph.D.- Chief Executive Officer Amb. Alan Holmer – Chairman of the Board Former CEO of PhRMA (1996-2005) Over two decades of public service in Washington, D.C. including Special Envoy to China (2007-2009) Former board member Inspire Pharma (sold to Merck for $430m i
Slide 21: World Class Scientific Advisors
21 World Class Scientific Advisors Sumner Burstein, Ph.D. - UMass Medical School Professor of Biochemistry and Pharmacology; inventor of Resunab Michael Knowles, M.D., Ph.D. - UNC Chapel Hill Professor of Pulmonary and Critical Care Medicine James Chmiel, M..D. – Case Western Reserve Medical School
Slide 22: Financial Profile
22 22 Financial Profile Stock Ticker: CRBP:OTCQB $77,400,000 Market capitalizationasof November 5,2014 $10,300,000 Raise from successful private placement (Q2 2014) from institutional and retail base 25,800,000 Common shares outstanding 41,500,000 Fully diluted shares outstanding (including warrants
Slide 23: Corbus Poised for Significant Upside
23 Corbus Poised for Significant Upside Recent Deals in CF and Fibrosis $8,300 $10,000 $1,000 $405 $444 $450 $100 Galapagos Galecto Amira Intermune (License -AbbVie) (M&A -BMS) (M&A -BMS) (M&A -Roche) Pre-Clinical Phase 1 Phase 3 Recent Deals Date Company Partner Type Drug Indication Stage Up-Front
Slide 24: Potential Value Indicators
24 Potential Value Indicators Market Cap of CF and Fibrosis Focused Companies $26,000 30000 $5,335 3000 $1,347 $685 $286 300 $77 30 Corbus ProQR Insmed PTC Intercept Vertex Phase 2a PC Phase 3 Market Recent IPO Date Company Lead Compound Indication Stage Market Cap 9/2014 ProQR QR-010 CysticFibrosis
Slide 25: Conclusions
25 Conclusions • Lead Product Resunab is a novel, safe and promisingly potent clinical stage anti-inflammatory/anti-fibrotic drug which acts to resolve inflammation • Targets multiple rare inflammatory indications • Proven safe in two Phase 1 trials • Promising potency in multiple pre-clinical model
Slide 26: Corbus Pharma, Norwood, MA contact
26 100 River Ridge Drive Norwood, MA 02062 www.CorbusPharma.com
Corbus Pharmaceuticals Holdings — Investor Presentation (November 2014) on 6ix